Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 10:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 25 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: quetiapine fumarate tablets Clear all
Completed Not applicable Interventional Results available

Quetiapine for the Reduction of Cocaine Use

NCT00631748
View directory record Official record
Conditions
Cocaine Dependence, Cocaine Abuse, Cocaine Addiction, Drug Abuse, Substance Abuse
Interventions
quetiapine fumarate, Matched Placebo, Cognitive-behavioral Therapy
Drug · Behavioral
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Mar 30, 2014 · Synced Sep 25, 2026, 10:56 PM EDT
Completed Phase 1 Interventional

Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants

NCT02087579
View directory record Official record
Conditions
Psychotic Disorders, Schizophrenia, Bipolar Disorder, Depressive Disorder
Interventions
Aripiprazole, oral formulation, Olanzapine, oral formulation, Paliperidone, oral formulation, Paliperidone, LAI, Quetiapine, oral formulation, Risperidone, oral formulation, Risperidone, LAI
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
6
States / cities
Garden Grove, California • Kissimmee, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Sep 25, 2026, 10:56 PM EDT
Completed Phase 3 Interventional

Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Children & Adolescents With Bipolar I Mania

NCT00090311
View directory record Official record
Conditions
Bipolar Disorder
Interventions
quetiapine fumarate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
10 Years to 17 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
32
States / cities
Scottsdale, Arizona • Riverside, California • Sacramento, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Sep 25, 2026, 10:56 PM EDT
Completed Phase 1 Interventional

A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard

NCT05402111
View directory record Official record
Conditions
Schizophrenia
Interventions
SEP-363856, Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
7
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Long Beach, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Sep 25, 2026, 10:56 PM EDT
Completed Phase 4 Interventional

Quetiapine Compared With Placebo in the Management of Fibromyalgia

NCT01458964
View directory record Official record
Conditions
Fibromyalgia
Interventions
Quetiapine
Drug
Lead sponsor
East Tennessee State University
Other
Eligibility
18 Years to 60 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Johnson City, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 8, 2014 · Synced Sep 25, 2026, 10:56 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform

NCT02431702
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders
Interventions
Aripiprazole, Haloperidol, Olanzapine, Oral Paliperidone ER, Perphenazine, Quetiapine, Oral Risperidone, Paliperidone Palmitate Injection (PP1M), Paliperidone Palmitate Injection (PP3M)
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 35 Years
Enrollment
337 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
34
States / cities
Little Rock, Arkansas • Garden Grove, California • Lemon Grove, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 25, 2026, 10:56 PM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine

NCT04164758
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Pimavanserin, Placebo, Quetiapine
Drug · Other
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
16
States / cities
Scottsdale, Arizona • Tucson, Arizona • Sacramento, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Sep 25, 2026, 10:56 PM EDT
Completed Phase 3 Interventional Results available

Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disorder

NCT00227305
View directory record Official record
Conditions
Schizophrenia, Bipolar I Disorder
Interventions
quetiapine fumarate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
10 Years to 17 Years
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
31
States / cities
Dothan, Alabama • Scottsdale, Arizona • Cerritos, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Sep 25, 2026, 10:56 PM EDT
Completed Phase 1 Interventional

A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia

NCT05542264
View directory record Official record
Conditions
Schizophrenia
Interventions
SEP-363856, Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Dayton, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Sep 25, 2026, 10:56 PM EDT
Completed Phase 3 Interventional

Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Adolescent Patients With Schizophrenia

NCT00090324
View directory record Official record
Conditions
Schizophrenia
Interventions
quetiapine fumarate tablets
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
13 Years to 17 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
23
States / cities
Dothan, Alabama • Cerritos, California • Riverside, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Sep 25, 2026, 10:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Clinical Study to Investigate the Effect of the Combination of Psychotropic Drugs and an Opioid on Ventilation

NCT04310579
View directory record Official record
Conditions
Hypercapnia, Ventilatory Depression
Interventions
Oxycodone and Midazolam, Oxycodone, Paroxetine, and Quetiapine
Drug
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 50 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Sep 25, 2026, 10:56 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Bipolar Depression

NCT00060489
View directory record Official record
Conditions
Bipolar Disorder, Depression, Bipolar
Interventions
SEROQUEL (quetiapine fumarate) Tablets
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
27
States / cities
Birmingham, Alabama • Beverly Hills, California • La Mesa, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2011 · Synced Sep 25, 2026, 10:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Crossover Bioequivalence Study of Quetiapine Fumarate 25 mg Tablets Under Fasted Conditions

NCT01570907
View directory record Official record
Conditions
Treatment for Bipolar I Disorder
Interventions
Quetiapine Fumarate
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 25, 2026, 10:56 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression

NCT04521478
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
BI 1358894, Placebo, Quetiapine
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 65 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
29
States / cities
Birmingham, Alabama • Garden Grove, California • Long Beach, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Sep 25, 2026, 10:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Quetiapine Fumarate Immediate Release (IR) Versus Extended Release (XR) Dose Escalation Comparison

NCT00702676
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Quetiapine Fumarate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 15, 2009 · Synced Sep 25, 2026, 10:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study Comparing Topical, Rectal, and Oral Quetiapine

NCT02131545
View directory record Official record
Conditions
Dementia, Delirium
Interventions
Quetiapine 25 mg gel applied topically, Quetiapine 25 mg tablet by mouth, Quetiapine 25 mg rectal suppository
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Sep 25, 2026, 10:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Crossover Bioequivalence Study of Quetiapine Fumarate 25 mg Tablets Under Fed Conditions

NCT01570894
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
Quetiapine Fumarate
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 25, 2026, 10:56 PM EDT
Completed Phase 4 Interventional

Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.

NCT00325689
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Quetiapine or Risperidone + Aripiprazole, Quetiapine or Risperidone + placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
48
States / cities
Little Rock, Arkansas • Cerritos, California • Costa Mesa, California + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2013 · Synced Sep 25, 2026, 10:56 PM EDT
Completed Not applicable Interventional

Crossover Bioequivalence Study of Quetiapine Fumarate 300 mg Tablets Under Steady State Fasted Conditions

NCT01570959
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
Quetiapine Fumarate
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
7
States / cities
Garden Grove, California • National City, California • North Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 25, 2026, 10:56 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Seroquel SR in the Treatment of Generalised Anxiety Disorder

NCT00389064
View directory record Official record
Conditions
Anxiety Disorders
Interventions
Quetiapine XR, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
66 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
14
States / cities
Fort Myers, Florida • Gainsville, Florida • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2012 · Synced Sep 25, 2026, 10:56 PM EDT
Completed Phase 2 Interventional

Bipolar Study of Seroquel XR With Pramipexole Dihydrochloride

NCT00893841
View directory record Official record
Conditions
Bipolar Depression
Interventions
quetiapine (Seroquel) XR, placebo, pramipexole dihydrochloride
Drug
Lead sponsor
Dr. D McIntosh & Dr. K Kjernisted Clinical Research Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
San Diego, California • Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Feb 3, 2013 · Synced Sep 25, 2026, 10:56 PM EDT
Terminated Phase 2Phase 3 Interventional

A Long-Term, Open-Label, Study on Schizophrenia

NCT01129674
View directory record Official record
Conditions
Schizophrenia
Interventions
LY2140023, Olanzapine, Aripiprazole, Risperidone, Quetiapine
Drug
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
42
States / cities
Little Rock, Arkansas • Escondido, California • Garden Grove, California + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 25, 2026, 10:56 PM EDT
Completed Phase 3 Interventional Results available

Treatment of Mania Symptoms With Drug Therapy

NCT00183443
View directory record Official record
Conditions
Bipolar Disorder, Schizophrenia
Interventions
Divalproex-extended release (DVP-ER), Lithium, Quetiapine
Drug
Lead sponsor
Palo Alto Veterans Institute for Research
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Sep 25, 2026, 10:56 PM EDT
Completed Phase 1 Interventional

Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder

NCT02901587
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Lu AF35700 (10 mg/day), Lu AF35700 (30 mg/day), Quetiapine (Seroquel XR® 800 mg/day)
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
21 Years to 60 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Sep 25, 2026, 10:56 PM EDT